Clinical Trial

Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals

Study acronym: LEOPOLD
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2015-06-10; most recent amendment 2025-09-04.
Status change: Not Yet Recruiting → Recruiting 2016-06-30
Trial Details
NCT Number NCT02472028
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Cerebrovascular Disorders
Enrollment 820 participants
Start Date 2015-09
Primary Completion 2028-09-11 (estimated)
Study Completion 2028-09-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-05